4058
Reliability of the compressed sensing MPRAGE for brain volume measurement: a comparison study with standard MPRAGE.1Chung-Ang University Hospital, Seoul, Korea, Republic of, 2Konkuk University Medical Center, Seoul, Korea, Republic of
Synopsis
Keywords: Dementia, Neurodegeneration
Motivation: T1 Magnetization Prepared Rapid Acquisition Gradient Echo (MPRAGE) with compress sensing (CS) offers high-contrast 3D images in a short time compared with standard MPRAGE. To utilize this in daily practice, comparison with existing method is essential.
Goal(s): We investigated agreement of volume data obtained by NeuroQuant and test the possibility of CS-MPRAGE as an alternative method to standard-MPRAGE.
Approach: We included 95 patients who underwent both CS-MPRAGE and standard-MPRAGE and compared the volume data.
Results: CS-MPRAGE yields comparable volumes to standard-MPRAGE for large brain region like the entire cortex. However, small structure such as hippocampus tends to measure smaller with CS-MPRAGE.
Impact: CS-MPRAGE offers high-quality 3D images and reliable volume data in significantly less time than standard-MPRAGE. This eliminates need for patients to remain still for extended periods, overcoming a major obstacle in imaging studies.
Introduction
Quantitative biomarker such as volume measurement is essential for various neurodegenerative disorder patients in diagnosis or prediction of disease progression. Introducing of high resolution MRI such as three dimensional T1 Magnetization Prepared Rapid Acquisition Gradient Echo (MPRAGE) made it possible to investigate not only anatomic morphology but also quantitative data combined with volume measure software. However, relatively long acquisition time requires patients to remain still for prolonged periods to ensure the adequate image quality which is one of the major obstacles to undergo the image study. In the last years, the compressed sensing (CS) acceleration technique has been combined with MPRAGE sequence and widely used in research field with great interest. However, to use the CS-accelerated version of the MPRAGE in clinical practice and potentially replace the standard-MPRAGE, further investigation is required. Therefore, we investigated agreement of volume data obtained by NeuroQuant and test the possibility of CS-MPRAGE as an alternative method to standard-MPRAGE.Methods
Total 95 patients (F:M = 57:38, 74.75±9.7 years) who underwent both standard-MPRAGE and CS-MPRAGE in our memory clinic were included in this study. For all subjects, MRI was performed on a clinical 3T MR scanner (MAGNETOM Vida Siemens Healthineers, Erlangen, Germany), using 64-channel multiarray receiver coil. NeuroQuant 3.1 was used for volumetric data analysis. Inter-method reliability was measured with Pearson correlation coefficient (r), intraclass correlation coefficient (ICC).Results
The mean acquisition time for the CS-MPRAGE (2’13’’) was significantly shorter (P < 0.001) than standard MPRAGE (5’ 42’’). The average entire cortical gray matter volume measure with CS-MPRAGE was smaller than that of standard-MRPAGE (425.49±52.04 vs. 429.61±52.54 mL), two sequences showed excellent reliability (r = 0.934; ICC 0.948-0.977; p<0.001). Normative percentile of hippocampus volume with standard-MPRAGE is 29.06 while that of CS-MPRAGE is 27.70. Two sequences showed moderate reliability (r = 0.697; ICC 0.544-0.798; p<0.001). Other structures such as cerebellum, basal ganglia, cerebellum, brain stem, ventricle presented similar volume between the two sequences (fig. 4).Discussion and conclusion
In this study, we compared NeuroQuant derived brain volume measurement using newly developed CS-MPRAGE sequence. Our findings demonstrate that CS-MPRAGE offers a comparable acquisition technique for daily clinical practice with patients at risk of neurodegenerative disorders. It shows comparable performance in volume measurement while maintaining good image quality and significantly reducing scan time compared to standard-MPRAGE. Neurodegenerative disorders are reliably characterized by progressive neural atrophy, quantifiable through MRI post-processing techniques such as brain volume measurement. In clinical practice, brain volume data offer insights into disease processes, identify risks of rapid clinical deterioration, and provide objective, quantitative evidence for prognosis. However, the relatively lengthy acquisition time for high-resolution images often deters patients from undergoing the imaging study. Our study showed that CS-MPRAGE performs similarly to standard-MPRAGE in measuring the volume of relatively large brain structures such as the entire cortex. However, smaller structures, such as the hippocampus, may register smaller measurement with CS-MPRAGE compared to standard-MPRAGE.Acknowledgements
No acknowledgement found.References
1. Ferraro PM, Gualco L, Costagli M, Schiavi S, Ponzano M, Signori A, et al. Compressed sensing (CS) MP2RAGE versus standard MPRAGE: A comparison of derived brain volume measurements. Physica Medica. 2022;103:166-74.
2. Trotier AJ, Dilharreguy B, Anandra S, Corbin N, Lefrançois W, Ozenne V, et al. The compressed sensing MP2RAGE as a surrogate to the MPRAGE for neuroimaging at 3 T. Investigative Radiology. 2022;57(6):366.
Figures
